Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer

预测、诊断和治疗儿童癌症幸存者心脏迟发效应的新方法

• 批准号: 234942
• 负责人: Nathan Paul C
• 金额: $ 147.72万
• 依托单位: Hospital for Sick Children (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2011
• 资助国家: 加拿大
• 起止时间: 2011-06-01 至 2016-06-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=234942&lang=en
• 关键词: Anthracycline Toxicity; Cardiac Biomarkers; Cardiac Dysfunction; Childhood Cancer Survivors; Echocardiography; Genomics; Pilot Intervention Study; Risk Prediction Model

Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death. Interventions that occur late in the evolution of treatment-related heart disease are usually ineffective at prev

癌症治疗可以使儿童癌症幸存者患心脏病的风险增加，这可能导致严重疾病或过早死亡。在治疗相关性心脏病进展的晚期进行干预，通常在早期无效。